The Evolving Role of Immune-Checkpoint Inhibitors in Malignant Pleural Mesothelioma.
Maxime BorgeaudFloryane KimAlex FriedlaenderFilippo LococoAlfredo AddeoKoen W W LansinkPublished in: Journal of clinical medicine (2023)
Malignant pleural mesothelioma (MPM) is a rare cancer usually caused by asbestos exposure and associated with a very poor prognosis. After more than a decade without new therapeutic options, immune checkpoint inhibitors (ICIs) demonstrated superiority over standard chemotherapy, with improved overall survival in the first and later-line settings. However, a significant proportion of patients still do not derive benefit from ICIs, highlighting the need for new treatment strategies and predictive biomarkers of response. Combinations with chemo-immunotherapy or ICIs and anti-VEGF are currently being evaluated in clinical trials and might change the standard of care in the near future. Alternatively, some non-ICI immunotherapeutic approaches, such as mesothelin targeted CAR-T cells or denditric-cells vaccines, have shown promising results in early phases of trials and are still in development. Finally, immunotherapy with ICIs is also being evaluated in the peri-operative setting, in the minority of patients presenting with resectable disease. The goal of this review is to discuss the current role of immunotherapy in the management of malignant pleural mesothelioma, as well as promising future therapeutic directions.
Keyphrases
- poor prognosis
- clinical trial
- end stage renal disease
- long non coding rna
- locally advanced
- current status
- healthcare
- ejection fraction
- induced apoptosis
- chronic kidney disease
- newly diagnosed
- palliative care
- cancer therapy
- photodynamic therapy
- papillary thyroid
- peritoneal dialysis
- quality improvement
- randomized controlled trial
- radiation therapy
- pain management
- cell cycle arrest
- squamous cell carcinoma
- patient reported outcomes
- vascular endothelial growth factor
- squamous cell
- chronic pain
- rectal cancer
- open label
- oxidative stress
- patient reported
- pi k akt